Risk and Return

Phantom Neuro is a neurotechnology company focused on developing innovative muscle-machine interfaces to enhance robotic limb rehabilitation. By integrating neurotechnology with robotic systems, Phantom Neuro aims to improve mobility for users through precise control of robotic limbs, facilitating more natural movement and enhancing user experiences. The company employs a minimally invasive approach, which allows for effective rehabilitation solutions that address the needs of individuals with mobility challenges. Additionally, Phantom Neuro explores various applications of its technologies within the broader field of assistive robotics, striving to provide valuable tools that help patients with limb deficits regain control over their lives and improve their overall quality of life.

Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.

Phantom Neuro is a neurotechnology company focused on developing innovative muscle-machine interfaces to enhance robotic limb rehabilitation. By integrating neurotechnology with robotic systems, Phantom Neuro aims to improve mobility for users through precise control of robotic limbs, facilitating more natural movement and enhancing user experiences. The company employs a minimally invasive approach, which allows for effective rehabilitation solutions that address the needs of individuals with mobility challenges. Additionally, Phantom Neuro explores various applications of its technologies within the broader field of assistive robotics, striving to provide valuable tools that help patients with limb deficits regain control over their lives and improve their overall quality of life.

Prepared is a company focused on enhancing public safety through innovative software solutions. It has developed a safety application that facilitates real-time communication during emergencies, particularly in school environments. The application enables teachers to connect directly with first responders, allowing for prompt reporting of emergencies and non-critical incidents. By providing access to vital information such as video, GPS location, and text communication from mobile 911 callers, Prepared aims to improve the efficiency of dispatchers and first responders. The company's mission centers on prioritizing safety and maximizing impact within communities, ensuring that individuals can work more effectively to save lives.

HAAS Alert is a prominent provider of mobility and smart city data services focused on enhancing safety for emergency crews, drivers, and the general public through Cellular Vehicle-to-Vehicle (V2V) communication. The company's Safety Cloud delivers real-time data that connects first responders and various fleets with motorists and autonomous vehicles, helping to prevent collisions and minimize traffic delays. HAAS Alert's platform issues preemptive notifications to drivers, alerting them to the approach of emergency vehicles via their car dashboards or smartphones. Additionally, the service supports smart city initiatives by providing valuable traffic information to government officials, aiding in infrastructure planning and real-time traffic management. HAAS Alert collaborates with the U.S. Department of Homeland Security on innovative safety solutions and has garnered support from notable safety organizations.

Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.